Yongin Severance hospital
Welcome,         Profile    Billing    Logout  
 58 Trials 
771 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Sang Il
NCT05199441: Efficacy of Galeo® in Patients With Postprandial Distress Syndrome Subtype in Functional Dyspepsia

Completed
4
226
RoW
Dihydroxydibutylether group, Galeo® group, Control group placebo, Placebo
Pusan National University Yangsan Hospital
Dyspepsia
07/23
07/23
NCT05701540: A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn

Recruiting
4
338
RoW
Tegoprazan, Esomeprazole
HK inno.N Corporation
Gastroesophageal Reflux Disease
12/24
12/24
OPTIMIZE-APT, NCT05418556: Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

Recruiting
4
3944
RoW
aspirin, clopidogrel, prasugrel, ticagrelor
Asan Medical Center
Coronary Artery Disease
08/27
12/28
NCT05051332: Phase 3 Clinical Trial of CartiLife® in Korea

Active, not recruiting
3
104
RoW
Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery
Biosolution Co., Ltd.
Articular Cartilage Defect, Articular Cartilage Degeneration
09/23
09/24
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT06466785: A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Recruiting
3
429
RoW
Efepoetin Alfa, GX-E4, Darbepoetin Alfa, Aranesp®
Genexine, Inc., PT Kalbe Genexine Biologics
Anemia of Chronic Kidney Disease
12/26
09/27
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Recruiting
3
408
RoW
Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine
GC Cell Corporation
Pancreatic Ductal Adenocarcinoma
12/26
06/27
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
09/25
NCT05944627: Evaluate Safety and Explore Efficacy of FURESTEM-OA Kit Inj. in Patients With Knee Osteoarthritis

Not yet recruiting
1/2
68
NA
FURESTEM-OA Kit Inj., Placebo
Kang Stem Biotech Co., Ltd.
Knee Osteoarthritis
03/24
02/26
NCT05045534: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects

Completed
1
96
RoW
Comparison of TB-840 treatment with Placebo, TB-840
Therasid Bioscience
Healthy Volunteers
08/22
12/22
NCT02601417: The Necessity of Bile Cultures in Patients With Acute Cholangitis

Active, not recruiting
N/A
440
RoW
Ignoring result of bile culture
Seoul National University Hospital
Acute Cholangitis
03/24
07/24
NCT04810312: Combined Exercise and Nutrition Intervention for Spinal Sarcopenia

Not yet recruiting
N/A
35
NA
Combined exercise and nutrition intervention
Seoul National University Hospital
Sarcopenia
03/22
05/22
NCT04416763: Diagnostic Value of Endoscopic Ultrasound Elastography and Contrast Enhanced Endoscopic Ultrasound for Differential Diagnosis of Gallbladder Polyp

Recruiting
N/A
30
RoW
Seoul National University Hospital
Gallbladder Polyps or Masses Greater Than 8-10 mm in Size
04/22
06/22
NCT04750044: Refeeding in Post-ERCP Pancreatitis

Recruiting
N/A
80
RoW
early refeeding, delayed refeeding
Yonsei University
Post-ERCP Pancreatitis
11/22
12/22
DENEX HTN-KORAS, NCT04307836: DENEX, Renal Denervation Therapy, in Patients With Hypertension on no or 1-3 Antihypertensive Medications

Recruiting
N/A
140
RoW
Renal Denervation
Kalos Medical
Hypertension, Vascular Diseases, Cardiovascular Diseases
07/23
04/24
NCT05220475: A Comparison of a Fully Covered Self-expandable Metal Stent With an External Anchoring Plastic Stent and Uncovered Stent

Recruiting
N/A
108
RoW
fully covered self-expandable metal stent with an anchoring external plastic stent, uncovered self-expandable metal stent
Seoul National University Hospital
Malignant Biliary Obstruction
10/23
10/24
NCT05544825: Ice Plant (Mesembryanthemum Crystallinum) Extract in Patients With Impaired Fasting Glucose

Completed
N/A
40
RoW
Ice plant group, Placebo group
Pusan National University Yangsan Hospital
Impaired Fasting Glucose
10/23
10/23
NCT06628791: BK329 and Body Fat Reduction

Enrolling by invitation
N/A
100
RoW
BK329, Placebo
Pusan National University Yangsan Hospital
Obesity and Overweight
12/24
12/24
NCT03775837: Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults

Recruiting
N/A
60
RoW
Panax Ginseng C.A. Mey Extract group, Placebo group
Pusan National University Yangsan Hospital
Liver Diseases
12/24
12/24
NCT04320199: Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease

Recruiting
N/A
30
RoW
Fermented Protaetia brevitarsis seulensis powder group, Placebo group
Pusan National University Yangsan Hospital
Alcoholic Liver Disease
12/24
12/24
NCT06091033: Perceived Stress and Black Rice (Oryza Sativa L.) Extract Fermented With Lactobacillus

Completed
N/A
80
RoW
Fermented rice, placebo
Pusan National University Yangsan Hospital
Perceived Stress
12/23
12/23
NCT05180136: Efficacy of Rice Bran Extract in Mildly to Moderately Depressed Adults

Completed
N/A
100
RoW
Rice bran extract group, Control group
Pusan National University Yangsan Hospital
Depression
12/22
12/22
NCT05548842: The Combined Seed Extracts of Cassia Obtusifolia Linne and Foeniculum Vulgare Mill in Patients With Chronic Constipation

Completed
N/A
100
RoW
The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill, Placebo group
Pusan National University Yangsan Hospital
Chronic Constipation
12/23
12/23
NCT05729867: Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC

Recruiting
N/A
50
RoW
Endoscpic biliary drainage using fully covered metal stent
Seoul National University Hospital
Malignant Biliary Obstruction, Hepatocellular Carcinoma
04/24
04/25
NCT06120348: Study of Application of Pulse Electrical Stimulation Around Eye in Dry Eye Disease Patients Who Are Scheduled for Laser Epithelial Keratomileusis (LASEK) Surgery

Recruiting
N/A
178
RoW
Charge-Balanced, Symmetric Nerve Stimulation, Sham Stimulation
Nu Eyne Co., Ltd.
Dry Eye Disease
04/24
08/24
NCT06427083: Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

Recruiting
N/A
240
RoW
Envlo Tablet, Envolomet SR Tablet
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
12/25
06/26
NCT06419816: Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus

Recruiting
N/A
480
RoW
Physician-managed "WellCheck" use, self-managed "WellCheck" use
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
12/25
06/26
NCT06628804: Artemisia and Green Tea Extracts for Gastric Mucosal Health

Enrolling by invitation
N/A
100
RoW
Artemisia and green tea extracts, Placebo
Pusan National University Yangsan Hospital
Functional Dysphonia
12/25
12/25
NCT06629805: β-glucan and Exercise on Musculoskeletal Function in Sarcopenic Adults

Enrolling by invitation
N/A
116
RoW
Aureobasidium pullulans produced β-glucan, Placebo
Pusan National University Yangsan Hospital
Sarcopenia
12/25
12/25
NCT05493904: PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)

Recruiting
N/A
320
RoW
OCT-guided PCI, Angiography-guided PCI, Drug-eluting stent
Chonnam National University Hospital, Abbott Medical Devices
Coronary Artery Disease, Angina Pectoris
08/24
12/26
NCT05065125: Clinical Usefulness of Digital Single-operator Cholangioscopy(SpyGlassâ„¢) for Post-liver Transplant Anastomotic Stricture

Recruiting
N/A
40
RoW
digital single-operator cholangioscopy
Seoul National University Hospital
Liver Transplant; Complications, Biliary Duct Obstruction, Anastomosis, Obstructed
09/24
12/24
NCT06630455: Meu-cinn for Gastric Mucosal Health in Adults With Functional Dyspepsia

Not yet recruiting
N/A
100
RoW
Meu-cinn, Placebo
Pusan National University Yangsan Hospital
Functioanl Dyspepsia
12/25
12/25
NCT05596370: Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer

Recruiting
N/A
150
RoW
cell free DNA in blood and urine, metabolite/microbiome in urine and stool
Seoul National University Hospital, DXOME CO., LTD.
Pancreatic Cancer, Cholangiocarcinoma, Gallbladder Cancer
12/24
12/24
DOSE, NCT05702060: Randomized Comparison of Radiation Exposure to Operators in Coronary Intervention Between Right Radial and Left DRA

Recruiting
N/A
1010
RoW
Radial Artery Puncture Method for Coronary Angiography and Intervention
Yonsei University, Myung In Pharm
Radiation Exposure
12/25
12/25
NCT05497271: Confirmation of Association Between Cystic Fluid Analysis With Pancreatic Cystic Lesions

Recruiting
N/A
500
RoW
Seoul National University Hospital
Pancreatic Cyst, Molecular, Chemical Analysis of Cystic Fluid
12/25
12/25
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD

Recruiting
N/A
2400
RoW
Percutaneous Coronary Intervention
Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd
Coronary Disease
12/26
07/30
DCB-HBR, NCT05221931: Drug-Coated Balloon in Patients With High Bleeding Risk

Recruiting
N/A
1350
RoW
Percutaneous coronary intervention
Samsung Medical Center, Seoul St. Mary's Hospital, Seoul National University Bundang Hospital, Korea University Ansan Hospital, Chonnam National University Hospital, Chung-Ang University Gwangmyeong Hospital, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gyeongsang National University Hospital, Uijeongbu St. Mary Hospital, Keimyung University Dongsan Medical Center, Inha University Hospital, Chungbuk National University, Wonju Severance Christian Hospital, SMG-SNU Boramae Medical Center, Kangbuk Samsung Hospital, Sungkyunkwan University, Ewha Womans University, Korea University Guro Hospital
Coronary Artery Disease
07/27
12/28
Symphony, NCT04912674: Evaluation of ™ Posterior Cervical System for Surgical Treatment of Adult Cervical Deformity

Recruiting
N/A
100
US
Symphony OCT System
International Spine Study Group Foundation, DePuy Synthes
Cervical Deformity
07/27
07/27
NCT06013306: Long-Term Follow-up Study of Subjects With Knee Osteoarthritis Who Had Administered FURESTEM-OA Kit Inj. in K0701 Study

Not yet recruiting
N/A
58
NA
Kang Stem Biotech Co., Ltd.
Knee Osteoarthritis
11/29
12/30
PCD 2, NCT04194996: Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0

Recruiting
N/A
200
US
Surgical intervention
International Spine Study Group Foundation, DePuy Synthes, Orthofix Inc.
Cervical Deformity
12/32
07/33
INCS/INAH, NCT05708157: Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

Recruiting
N/A
240
RoW
concomitant intranasal antihistamine and corticosteroid
Gachon University Gil Medical Center, Hallym University Kangnam Sacred Heart Hospital, Gangneung Asan Hospital, Bundang Jesaeng Hospital, Chung-Ang University Gwangmyeong Hospital, Hallym University Medical Center
Allergic Rhinitis
02/24
02/24
NCT05604573: DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer

Recruiting
N/A
150
RoW
cell free DNA in blood, genetic mutation in tissue
Seoul National University Hospital, GENECAST Co., Ltd.
Pancreatic Cancer
12/24
12/24
Kim, Jin Seok
KONCLUDE, NCT02843191: Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy

Active, not recruiting
3
358
RoW
Chemotherapy
Kyung Hee University Hospital at Gangdong, Korean Society of ColoProctology, Pharmbio Korea Inc., Samjin Pharmaceutical Co., Ltd., Boryung Pharmaceutical Co., Ltd, JW Pharmaceutical
Rectal Cancer
07/23
06/26
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/25
08/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
CLAUDIA, NCT05534087: Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

Recruiting
3
236
RoW
mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy
Seoul National University Hospital
Colon Cancer
09/28
09/30
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
NCT03597087: The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study

Not yet recruiting
2
289
RoW
Anesthesia before transurethral resection of the bladder tumor, Anesthesia
Seoul National University Hospital
Bladder Cancer
07/21
12/22
NaliCap, NCT04371224: (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

Recruiting
2
200
RoW
Irinotecan Liposomal Injection [Onivyde], nal-IRI, Capecitabine, xeloda, 5-fluorouracil, 5FU, Leucovorin, LV
Seoul National University Hospital
Pancreatic Cancer
12/24
12/25
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
LINKER-MM1, NCT03761108 / 2018-003188-78: Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Checkmark Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Checkmark Completion of enrollment of trial for r/r multiple myeloma
Dec 2022 - Dec 2022: Completion of enrollment of trial for r/r multiple myeloma
Checkmark Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2021
More
Recruiting
1/2
387
Europe, Japan, US, RoW
Linvoseltamab, REGN5458
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Multiple Myeloma
05/32
06/32
NCT04492033: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Terminated
1/2
41
RoW
CTX-009 (ABL001), Paclitaxel, Irinotecan
Handok Inc., Compass Therapeutics, ABL Bio, Inc.
P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
01/24
01/25
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
ACCENT, NCT05355298: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

Recruiting
1/2
62
RoW
AMP945 ascending doses, AMP945 RP2D
Amplia Therapeutics Limited
Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma
05/25
05/25
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
148
RoW
HM95573, cobimetinib, HM95573, cetuximab
Hanmi Pharmaceutical Company Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor
09/24
12/24
DREAMM 9, NCT04091126 / 2019-003047-30: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Checkmark From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Recruiting
1
144
Europe, Canada, US, RoW
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
11/24
06/25
DREAMM 13, NCT04398680: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

Recruiting
1
28
Europe, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
11/25
11/25
NCT04722705: Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention

Recruiting
N/A
30
RoW
fractional Er:YAG laser, Matrixell, Medro corp., Seoul, Korea, Intense pulse light, IPL (Ellipse Flex, DDD, Hoersholm, Denmark)
Hallym University Kangnam Sacred Heart Hospital
Intense Pulsed Light, Erbium-yttrium Aluminum Garnet Laser, Scar Prevention
11/21
11/21
NCT04337333: Two-in-one Covered and Uncovered Metal Stent

Recruiting
N/A
100
RoW
Two-in-one stent
Ajou University School of Medicine
Extrahepatic Bile Duct Cancer, Pancreatic Cancer, Lymph Node Metastases, Gallbladder Cancer
12/21
12/21
NCT04835467: First-In-Human Intracoronary OCT-FLIm In Patients Undergoing PCI

Completed
N/A
40
RoW
Dual-modal OCT-FLIm
Korea University Guro Hospital
Atherosclerosis Coronary Artery With Angina Pectoris, Atheroscleroses, Coronary, Atherosclerotic Plaque, Thin-cap fIbroatheroma, Atherosclerosis
08/22
10/23
VISION, NCT04151615: VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

Completed
N/A
203
RoW
Boryung Pharmaceutical Co., Ltd
Multiple Myeloma
01/23
01/23
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Approved for marketing
N/A
Europe, Canada, US, RoW
Olaratumab, LY3012207
Eli Lilly and Company
Soft Tissue Sarcoma
 
 
NCT04853511: Comprehensive Assessment of Interconnection Between Brain Emotional Activity and Coronary Plaque Instability

Recruiting
N/A
200
RoW
OCT-FLIM (optical coherence tomography-fluorescence life time), 18F-FDG-PET/CT (positron emission tomography-computed tomography)
Korea University Guro Hospital
Atherosclerosis, Coronary, Emotional Stress, Inflammation, Hematopoiesis, Atherosclerosis Coronary Artery With Angina Pectoris, Atheroma; Heart, Atherosclerosis, Acute Coronary Syndrome
12/23
12/24
Choi, Donghoon
SEVEN-BOX, NCT05006027: Feasibility of PCI Using a 7-Fr Thin-Walled Sheath Via the DRA

Active, not recruiting
N/A
100
RoW
Percutaneous coronary intervention via the distal radial approach
Yonsei University, Severance Hospital, Merit Medical Systems, Inc.
Coronary Artery Disease, Distal Radial Artery, Complex Intervention
07/24
10/24
ONYSOVER, NCT05340361: Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT

Recruiting
N/A
30
RoW
Optical coherence tomography-guided percutaneous coronary intervention, Zotarolimus-eluting stent (Onyx family stent, Medtronic, Santa Rosa, CA, USA), Optical coherence tomography-guided Onyx family stent expansion
Yonsei University, Severance Hospital, Medtronic
Coronary Artery Disease, Optical Coherence Tomography, Stent
12/25
12/25
ICE-HEAT, NCT05421169: Diastolic Hyperemia-Free Ratio in Patients With CAD

Completed
N/A
300
RoW
diastolic hyperemia-free ratio (DFR)
Yonsei University, Severance Hospital, Boston Scientific Corporation
Coronary Stenosis, Coronary Artery Disease
02/24
03/24
NCT02748226: Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA): (A Retrospective & Prospective Observational Study)

Recruiting
N/A
12000
RoW
endovascular treatment
Yonsei University
Peripheral Arterial Disease(PAD)
07/27
07/27
Cho, Deok Yeon
NCT05910476: Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)

Recruiting
4
200
RoW
a high dose of statin/ezetimib
Yonsei University, dotter
Coronary Artery Disease, Dyslipidemias
09/26
09/26
DOSE, NCT05702060: Randomized Comparison of Radiation Exposure to Operators in Coronary Intervention Between Right Radial and Left DRA

Recruiting
N/A
1010
RoW
Radial Artery Puncture Method for Coronary Angiography and Intervention
Yonsei University, Myung In Pharm
Radiation Exposure
12/25
12/25
NCT05776550: Safety and Efficacy of Distal Radial Approach (SAFE-BOX)

Recruiting
N/A
3600
RoW
Yonsei University
Safety, Efficacy
05/26
05/26
MASTER, NCT05677711: Safety and Efficacy of the Ultimaster Stent

Active, not recruiting
N/A
204
RoW
ultimaster
Yonsei University, Terumo Corporation
Coronary Artery Disease, Drug-eluting Stents
02/25
02/25
NCT05658250: CREATE Trial, Prospective, Observational Study

Recruiting
N/A
300
RoW
CRE8 polymer-free Amphilimus-eluting stent, Cre8 evo stent
Yonsei University, Dio
Coronary Artery Disease, Drug Eluting Stent
12/27
12/27
Cho, Deok-Kyu
ASSURE-DES, NCT02797548: Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery

Completed
4
1010
RoW
Aspirin only, No antiplatelet therapy
Jung-min Ahn, CardioVascular Research Foundation, Korea
Antiplatelet Drugs
05/24
05/24
C-STAR, NCT05661552: Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

Active, not recruiting
4
108
RoW
Evolocumab 140 MG/ML, REPATHA® (Amgen Inc, Thousand Oaks, California, USA), Rosuvastatin 5mg, Ezetimibe 10mg
Yonsei University, Daewoong Pharmaceutical Co. LTD.
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
03/25
11/25
SEVEN-BOX, NCT05006027: Feasibility of PCI Using a 7-Fr Thin-Walled Sheath Via the DRA

Active, not recruiting
N/A
100
RoW
Percutaneous coronary intervention via the distal radial approach
Yonsei University, Severance Hospital, Merit Medical Systems, Inc.
Coronary Artery Disease, Distal Radial Artery, Complex Intervention
07/24
10/24
ONYSOVER, NCT05340361: Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT

Recruiting
N/A
30
RoW
Optical coherence tomography-guided percutaneous coronary intervention, Zotarolimus-eluting stent (Onyx family stent, Medtronic, Santa Rosa, CA, USA), Optical coherence tomography-guided Onyx family stent expansion
Yonsei University, Severance Hospital, Medtronic
Coronary Artery Disease, Optical Coherence Tomography, Stent
12/25
12/25
ROAD-IFR, NCT05682118: Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve

Recruiting
N/A
226
RoW
roadmap, iFR/FFR
Yonsei University, Philips Healthcare
Ischemic Heart Disease
11/25
11/25
ICE-HEAT, NCT05421169: Diastolic Hyperemia-Free Ratio in Patients With CAD

Completed
N/A
300
RoW
diastolic hyperemia-free ratio (DFR)
Yonsei University, Severance Hospital, Boston Scientific Corporation
Coronary Stenosis, Coronary Artery Disease
02/24
03/24
NCT05448625: Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)

Recruiting
N/A
200
RoW
Genoss DES
Yonsei University, Severance Hospital, Genoss Co., Ltd.
Drug-eluting Stent, Coronary Artery Disease
12/24
12/26
GENISPIRE, NCT05656118: Safety and Efficacy of Paclitax Coated Balloon in Patients With Coronary In-stent Restenosis (ISR)

Recruiting
N/A
260
RoW
Genoss® DCB
Yonsei University
In-stent Restenosis
03/26
03/26
Seo
STAMP, NCT05529056: Study of Atropine Therapeutic Effect on Myopic Progression

Recruiting
3
472
RoW
Atropine Sulfate 01, LPTAT01, Atropine Sulfate 02, LPTAT02, Atropine Sulfate 03, LPTAT03, Placebo, LPTAT04
LitePharmTech Co., Ltd.
Myopia, Children
06/23
12/23
JS-CT-2024-02, NCT06591221: The Effectiveness of Chuna Maintenance Therapy for Chronic Bothersome Neck Pain

Recruiting
N/A
250
RoW
Chuna Maintenance Therapy
Jaseng Medical Foundation
Neck Pain, Chronic Pain
12/25
12/25
NCT06734858: Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder Symptoms

Recruiting
N/A
110
RoW
SAT014, Control
S-Alpha Therapeutics, Inc.
Post-traumatic Stress Disorder, Adjustment Disorders
07/25
10/25
Jung, In Ae
VICTORY, NCT05851183: Effect of Vitis Vinifera Seed Extract on Venous Reflux Time in Varicose Vein

Recruiting
4
200
RoW
Vitis Vinifera seed extract medication plus therapeutic lifestyle change, Entelon® medication plus therapeutic lifestyle change, Therapeutic lifestyle change only
Yonsei University
Varicose Veins of Lower Limb
01/25
04/25
AIGatekeeper, NCT06178900: Evaluating AI-Gatekeeper Software in Coronary Artery Stenosis Screening: A Multicenter RCT

Recruiting
N/A
450
RoW
Assisted by the AI-Gatekeeper software group
INFINITT Healthcare, Korea Medical Device Development Fund
Coronary Artery Disease, Diagnosis
03/25
12/25
Kim, Jakyung
Cellgram-LC, NCT04689152: Clinical Trial to Evaluate the Efficacy and Safety of Administration in Patients With Alcoholic Cirrhosis

Recruiting
3
200
RoW
Cellgram-LC, Autologous bone marrow-derived mesenchymal stem cell
Pharmicell Co., Ltd.
Alcoholic Cirrhosis
08/27
01/28
 

Download Options